Last updated: July 17, 2026
Executive summary: SUTAB is the oral low-volume bowel preparation regimen (osmotic laxative salts) sold in the US for colon cleansing prior to colonoscopy. Commercial upside is primarily driven by (1) formulary adoption versus MiraLAX-based and other prescription regimens, (2) competitive pricing and payer coverage, (3) persistence of branded exclusivity through FDA and patent calendars, and (4) launch/entry timing for authorized or generic low-volume competitors that can compress net pricing. For investors, the core diligence is time-to-competitive pressure: Orange Book and exclusivity schedules determine when generics or AB-labeled products can erode premium pricing, while patient tolerability and administration logistics determine whether SUTAB maintains share against substitutes.
What patents protect SUTAB (sodium sulfate, potassium sulfate, magnesium sulfate) and how strong is the patent estate?
Featured snippet answer: SUTAB’s US IP posture is concentrated in formulation, composition-of-matter for specific salt mixtures, manufacturing/process improvements, and methods of use for bowel cleansing regimens. The practical investment relevance is whether any listed Orange Book patents remain enforceable through the next generic challenge window.
What to check in the Orange Book for SUTAB
For a complete estate-strength view, diligence focuses on:
- Listed drug substance and drug product patents (active ingredient salts and final combination).
- Method-of-use patents (dosing schedule prior to colonoscopy).
- Exclusivity-driven inventory risk (if applicable, exclusivity can outlast patents).
- Patent “reach”: claims that cover low-volume split-dose regimens versus broader bowel-prep activities.
How patent strength maps to investor risk
Patent estate strength influences:
- Paragraph IV probability: fewer enforceable, non-obvious, and claim-relevant patents reduces likelihood of first-wave generic entry.
- Carve-out leverage in settlements: broader claims and strong infringement positions increase settlement value and delay.
- Design-around feasibility: if substitutes can tweak ratios, granulation, or dosing steps without leaving the claim scope, generics can launch earlier via non-infringing AB pathways.
Jurisdiction and enforcement
- US: Orange Book-listed patents drive US generics exposure.
- Litigation jurisdiction: US district courts for ANDA disputes; ITC is possible but less common for established bowel prep products.
When does SUTAB lose exclusivity and what are the key expiration dates for patents and regulatory exclusivities?
Featured snippet answer: SUTAB loses exclusivity when the last enforceable Orange Book patent expires and any pediatric or other regulatory exclusivities end, enabling generic ANDA approval and potential commercial launch.
Exclusivity timeline mechanics
Investment models should separate:
- Patent expiration date (enables ANDA approvals post-expiration if no injunction).
- Market entry timing (typically after ANDA approval and launch readiness).
- Injunction/settlement impact (can push launch beyond expiration).
How to build a calendar for scenario analysis
- Create a backward-looking calendar from the earliest ANDA “permission to market” date derived from:
- last Orange Book patent expiration, and
- any exclusivity extensions (if applicable to the reference product).
- Overlay likely settlement corridors based on observed generic behavior for similar bowel-prep classes: first filers often negotiate for launch dates with shared product-market dynamics.
(No Orange Book patent numbers or dates are provided in the prompt; without them, an exact exclusivity and expiration schedule cannot be stated.)
What generic entry risks exist for SUTAB, including Paragraph IV challenges and authorized generics?
Featured snippet answer: The highest risk to SUTAB pricing and volume is first-wave ANDA entry, typically after a Paragraph IV challenge when the FDA approves an AB-rated generic for the same dosage regimen and labeling.
Entry vectors
- ANDA filing for bioequivalent salts with the same intended use and dosing schedule.
- Authorized generic via label partnerships or licensing arrangements.
- Non-ANDA substitutes in practice: patients and clinicians switch between bowel prep products through formulary rules even without true generic equivalence.
What makes bowel-prep competition fast
- Competitive products are often “switchable” within therapeutic intent (colon cleansing before colonoscopy).
- Payer contracts can move volume quickly if a lower price regimen has equivalent tolerability and convenience.
Key litigation questions for investors
- Were any Paragraph IV cases filed against SUTAB?
- Did settlement agreements include no-AG periods or agreed design-around boundaries?
- Did courts issue stay/consent injunctions that delay launch?
(No case identifiers, filings, or settlement terms are provided in the prompt; without them, this cannot be populated accurately.)
What is the FDA regulatory status of SUTAB and what pathway does it use?
Featured snippet answer: SUTAB is an FDA-approved prescription bowel cleansing regimen. Its regulatory status matters for generic entry because ANDA approvals can follow the reference product’s patent and exclusivity timelines.
Regulatory fundamentals investors model
- Approval pathway history impacts the availability of certain exclusivity protections.
- Labeling dictates clinical and payer adoption and constrains generic “label carve-outs” that can slow substitution.
- Post-marketing commitments and safety signals influence formulary confidence and launch timing for competitors.
Safety and tolerability as commercial variables
Bowel preps face:
- GI adverse event profiles that affect adherence and patient satisfaction.
- Real-world delays or reduced use if tolerability is inferior to alternatives.
What formulations are protected by SUTAB patents, including split-dose regimens and tablet mechanics?
Featured snippet answer: The most valuable IP for SUTAB typically covers the specific low-volume salt combination and the administration scheme that achieves bowel cleansing with split dosing.
Formulation risk factors for generics
Competitors can attempt:
- Salt ratio changes that may avoid claim scope.
- Particle size, granulation, coating, and dissolution profiles to match exposure while changing manufacturing steps.
- Dosing instructions variations that can trigger method-of-use issues if claims cover the regimen.
How to diligence “practical infringement”
- Compare generic labels: dose count, timing, and patient instructions.
- Compare product engineering: tablets, packaging, and instructions that drive actual administration.
- Review whether any method-of-use claims exist that map to clinical instruction text.
(No specific SUTAB patent claim set or formulation patent list is provided in the prompt.)
How does SUTAB compare with MiraLAX-based regimens and other bowel-prep products on price, convenience, and payer adoption?
Featured snippet answer: SUTAB’s value proposition is a low-volume, tablet-based prescription regimen that can be easier than powder-only or higher-volume options. Competitive outcomes depend on whether payers treat it as preferred versus “step therapy” to older, cheaper regimens.
Competitive set investors should benchmark
- OTC osmotic options used off-protocol (often not identical dosing).
- Prescription low-volume regimens in the same bowel prep use case.
- Split-dose protocols favored in practice for improved tolerability.
Key commercial KPIs
- Net price and rebates versus list price.
- Formulary placement (preferred versus non-preferred tiers).
- Prescriber preference at GI clinics, ambulatory surgery centers, and endoscopy units.
- Market share by channel (retail, mail, institution).
What drives share shifts
- Payer switching programs and rebates tied to GI clinic adoption.
- Stock availability and packaging size.
- Patient adherence and reduced repeat-prep costs (hidden economics for systems).
(Specific SUTAB revenue, market share, and contract terms are not provided in the prompt.)
Which companies challenge SUTAB, and what does SUTAB patent litigation look like?
Featured snippet answer: The competitive and legal risk is tied to which ANDA filers are targeting SUTAB and whether courts enjoin launches. Litigation posture is central to launch forecasting.
What the litigation record typically reveals
- Infringement and claim construction outcomes.
- Potential design-around paths accepted by courts or reflected in settlements.
- Stays pending appeal that extend exclusivity in practice.
(No litigation case numbers, defendants, or settlement dates are provided in the prompt.)
What settlement agreements or consent decrees could delay SUTAB generic launches?
Featured snippet answer: Settlements can set agreed launch dates, stipulate non-infringing changes, and include no-AG or partial-AG terms that materially shift generic entry timing relative to patent expiration.
Settlement features investors track
- Agreed market entry date independent of patent expiration.
- Scope limitations tied to labeling or manufacturing.
- Remedies if a generic deviates from agreed parameters.
- Cross-license terms or supply restrictions.
(No settlement terms are provided in the prompt.)
What generic entry risks exist for SUTAB beyond patents, including labeling carve-outs and bioequivalence barriers?
Featured snippet answer: Even with patent expiration, generics can face delays from labeling differences and bioequivalence performance, but for salts-like bowel preps, the dominant driver is typically IP and labeling.
Bioequivalence and manufacturing realities
- Demonstrating consistent dissolution/exposure across batches.
- Tablet mechanics and dissolution profiles.
- Stability and shelf-life packaging requirements.
Labeling constraints
If patents cover dosing schedules, generics may need label changes that can slow payer adoption even after approval.
(No SUTAB-specific generic approval history is provided in the prompt.)
Revenue exposure: how sensitive is SUTAB to pricing pressure, generic substitution, and payer shifts?
Featured snippet answer: Revenue exposure rises sharply when (1) SUTAB loses preferred formulary status or (2) a lower-priced generic enters with equivalent dosing instructions. The exposure curve is steeper for bowel preps because prescribers and clinics can switch quickly.
Model the revenue sensitivity drivers
- Short-term: rebate renegotiations and tender outcomes.
- Mid-term: formulary changes after competitor launches.
- Long-term: retention through clinical habit and patient experience.
Investment implications
- In a base case, SUTAB’s premium pricing can persist while IP blocks AB-labeled entry.
- In downside scenarios, first-wave competition compresses net pricing and reduces share in retail and institution channels.
(No financials are provided in the prompt.)
Which geographic markets have the highest competitive risk for SUTAB?
Featured snippet answer: US is the primary determinant for modeled exclusivity, because ANDA and Orange Book frameworks control generic timelines. International risk depends on local approvals and patent enforcement landscapes.
US-first logic
- ANDA approval is tied to US reference product patents listed in the Orange Book.
- US settlements and court injunctions directly control launch timing.
International watchpoints
- If equivalent approvals exist in EU/UK/Canada, timelines can diverge from the US but still pressure global reference pricing expectations.
(No SUTAB international filings or patent status are provided in the prompt.)
Key Takeaways
- SUTAB’s investment risk is dominated by IP calendar clarity (Orange Book-listed patents and any regulatory exclusivities) and generic entry timing, not by day-to-day clinical development.
- Commercial outcomes depend on payer preference durability versus competing bowel-prep regimens and the speed of formulary-driven substitution after generics or lower-priced prescription alternatives enter.
- Litigation and settlements can materially shift launch windows relative to patent expiration.
- The diligence priority is mapping Orange Book patents to generic risk pathways (ANDA, label carve-outs, and settlement-driven launch dates).
FAQs
- How do Orange Book patent listings for bowel-prep products typically affect ANDA launch timing?
- What label elements for split-dose bowel cleansing regimens most commonly constrain generic substitution?
- Do settlements for reference drugs in the bowel-prep category usually include no-AG terms, and how does that affect downside pricing scenarios?
- How should investors quantify net pricing compression risk for prescription bowel preparations after generic entry?
- What real-world adherence and tolerability factors most influence formulary adoption for low-volume bowel prep regimens like SUTAB?
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
- FDA. ANDA (Abbreviated New Drug Application) Process Overview. US Food and Drug Administration.
- FDA. Drugs@FDA. US Food and Drug Administration.
(No SUTAB-specific Orange Book patent numbers, expiration dates, FDA approval dates, litigation case names, or settlements were included in the prompt, so this analysis cannot populate exact calendared dates or named parties without risking inaccuracy.)
